15 September 2017

Oxford BioDynamics Plc

Directorate update

Oxford BioDynamics Plc ('OBD' or the 'Company'), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, is pleased to announce that further to the announcement on 30 June 2017, Paul Stockdale will join the Company as Chief Financial Officer and an Executive Director on the Board, with immediate effect.

For further details contact:

Oxford BioDynamics Plc

+44 (0)1865 518910

Christian Hoyer Millar, CEO

Paul Stockdale, CFO

Stifel Nicolaus Europe Limited

+44 (0)20 7710 7600

Nominated Advisor and Broker

David Arch

Jonathan Senior

Peter Lees

Ben Maddison

Shore Capital

+44 (0)20 7408 4090

Joint Broker

Bidhi Bhoma

Edward Mansfield

FTI Consulting

+44 (0)20 3727 1000

Financial Public Relations Advisor

Julia Phillips

Brett Pollard

Natalie Garland-Collins

Appendix - Schedule Two Information

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. Paul Leslie Stockdale, aged 42 years, has been a director of the following companies during the five years preceding the date of this announcement:

Current directorships

Past Directorships

None

PL & JE Services Limited

The Company confirms that there is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) ('Oxford BioDynamics') is a revenue‐generating biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.

The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.

In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker 'OBD'. For more information please visitwww.oxfordbiodynamics.com.

Oxford Biodynamics plc published this content on 15 September 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 15 September 2017 06:08:03 UTC.

Original documenthttp://otp.investis.com/clients/uk/oxford_biodynamics_plc/rns/regulatory-story.aspx?cid=2040&newsid=925393

Public permalinkhttp://www.publicnow.com/view/CCD8D95A9CB2F37A6E16CE618CCE6FA0DB4A3CDC